Literature DB >> 19180469

Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis.

Jesse Rowley1, Archana Monie, Chien-Fu Hung, T-C Wu.   

Abstract

IL-15 and IL-15 receptor alpha (IL-15RA) play a significant role in multiple aspects of T-cell biology. However, given the evidence that IL-15RA can present IL-15 in trans, the functional capacity of IL-15RA expressed on CD8(+) T cells to modify IL-15 functions in cis is currently unclear. In the current study, we explore the functional consequences of IL-15RA, expression on T cells using a novel method to transfect naive CD8(+) T cells. We observed that RNA nucleofection led to highly efficient, non-toxic, and rapid manipulation of protein expression levels in unstimulated CD8(+) T cells. We found that transfection of unstimulated CD8(+) T cells with IL-15RA RNA led to enhanced viability of CD8(+) T cells in response to IL-15. Transfection with IL-15RA enhanced IL-15-mediated phosphorylation of STAT5 and also promoted IL-15-mediated proliferation in vivo of adoptively transferred naïve CD8(+) T cells. We demonstrated that IL-15RA can present IL-15 via cis-presentation on CD8(+) T cells. Finally, we showed that transfection with a chimeric construct linking IL-15 to IL-15RA cell autonomously enhances the viability and proliferation of primary CD8(+) T cells and cytotoxic potential of antigen-specific CD8(+) T cells. The clinical implications of the current study are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19180469      PMCID: PMC3004157          DOI: 10.1002/eji.200838594

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  49 in total

1.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

2.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

Review 3.  IL-15/IL-15 receptor biology: a guided tour through an expanding universe.

Authors:  Vadim Budagian; Elena Bulanova; Ralf Paus; Silvia Bulfone-Paus
Journal:  Cytokine Growth Factor Rev       Date:  2006-06-30       Impact factor: 7.638

4.  A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes.

Authors:  Niels Schaft; Jan Dörrie; Ina Müller; Verena Beck; Stefanie Baumann; Tanja Schunder; Eckhart Kämpgen; Gerold Schuler
Journal:  Cancer Immunol Immunother       Date:  2005-12-13       Impact factor: 6.968

5.  High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.

Authors:  Yangbing Zhao; Zhili Zheng; Cyrille J Cohen; Luca Gattinoni; Douglas C Palmer; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2005-09-02       Impact factor: 11.454

6.  Human T cells constitutively express IL-15 that promotes ex vivo T cell homeostatic proliferation through autocrine/juxtacrine loops.

Authors:  María-Eugenia Miranda-Carús; Marta Benito-Miguel; Miguel A Llamas; Alejandro Balsa; Emilio Martín-Mola
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

7.  Signaling T-cell survival and death by IL-2 and IL-15.

Authors:  Elizabeth Zambricki; Alana Shigeoka; Hidehiro Kishimoto; Jon Sprent; Steven Burakoff; Charles Carpenter; Edgar Milford; Dianne McKay
Journal:  Am J Transplant       Date:  2005-11       Impact factor: 8.086

8.  Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.

Authors:  Erwan Mortier; Agnès Quéméner; Patricia Vusio; Inken Lorenzen; Yvan Boublik; Joachim Grötzinger; Ariane Plet; Yannick Jacques
Journal:  J Biol Chem       Date:  2005-11-11       Impact factor: 5.157

9.  Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease.

Authors:  A Di Sabatino; R Ciccocioppo; F Cupelli; B Cinque; D Millimaggi; M M Clarkson; M Paulli; M G Cifone; G R Corazza
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

10.  Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.

Authors:  Ryan M Teague; Blythe D Sather; Jilian A Sacks; Maria Z Huang; Michelle L Dossett; Junko Morimoto; Xiaoxio Tan; Susan E Sutton; Michael P Cooke; Claes Ohlén; Philip D Greenberg
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

View more
  27 in total

1.  IL-15 receptor α signaling constrains the development of IL-17-producing γδ T cells.

Authors:  Sara L Colpitts; Lynn Puddington; Leo Lefrançois
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

2.  Inhibition of type 1 diabetes by upregulation of the circadian rhythm-related aryl hydrocarbon receptor nuclear translocator-like 2.

Authors:  Chen-Xia He; Nicolas Prevot; Christian Boitard; Philip Avner; Ute C Rogner
Journal:  Immunogenetics       Date:  2010-07-30       Impact factor: 2.846

Review 3.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

Review 4.  IL-2 and Beyond in Cancer Immunotherapy.

Authors:  John M Wrangle; Alicia Patterson; C Bryce Johnson; Daniel J Neitzke; Shikhar Mehrotra; Chadrick E Denlinger; Chrystal M Paulos; Zihai Li; David J Cole; Mark P Rubinstein
Journal:  J Interferon Cytokine Res       Date:  2018-02       Impact factor: 2.607

Review 5.  The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.

Authors:  Thomas A Waldmann
Journal:  Cancer Immunol Res       Date:  2015-03       Impact factor: 11.151

Review 6.  Adoptive immunotherapy for cancer or viruses.

Authors:  Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June
Journal:  Annu Rev Immunol       Date:  2014-01-09       Impact factor: 28.527

Review 7.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

Review 8.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.

Authors:  Michael Kalos; Carl H June
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 9.  Trans-presentation: a novel mechanism regulating IL-15 delivery and responses.

Authors:  Spencer W Stonier; Kimberly S Schluns
Journal:  Immunol Lett       Date:  2009-10-07       Impact factor: 3.685

10.  Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Authors:  A Pato; G Eisenberg; A Machlenkin; A Margalit; G Cafri; S Frankenburg; S Merims; T Peretz; M Lotem; G Gross
Journal:  Clin Exp Immunol       Date:  2015-08-28       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.